RESULTS

Impact of one-carbon metabolism-driving epitranscriptome as a therapeutic target for gastrointestinal cancer (Int. J. Mol. Sci., 2021, in press)

In the international collaboration with Hirotsu Bio Science Inc., Kinshu-kai Medical Corporation, IDEA Consultants Inc., Kyowa-kai Medical Corporation, Unitech Co. Ltd., as well as department of gastroenterology (Profs Yuichiro Doki and Hidetoshi Eguchi), Takeda et al. reviewed recent advances of the study of one-carbon metabolism-driving epitranscriptome in gastrointestinal cancer as a therapeutic target.